Neglected Tropical Diseases FORUM
Impact of Multi–Sector Partnerships

October 26 - 27, 2017 | Hyatt Regency Boston Harbor | Boston, MA

Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL
Wiweka Kaszubska, Ph.D., Vice President, Head of Product Development, MEDICINES FOR MALARIA VENTURE (MMV)
Leslie Wise, Vice President of Global Healthcare Economics, ANGIODYNAMICS

Veronica Arroyave, Director, Corporate Responsibility, ABBVIE

Anna Kravets, Director of Business Consulting, MERCK
Marco Biamonte, President and Founder, DRUGS & DIAGNOSTICS FOR TROPICAL DISEASES
Elizabeth (E.J) Ashbourne, Executive Director, PARTNERSHIP FOR QUALITY MEDICAL DONATION (PQMD)

Fabiana Rocha, Drug Development, CLINICAL MANAGER, DRUGS FOR NEGLECTED DISEASES INITIATIVE–DNDI
Dear Colleague,

A successful neglected tropical disease (NTD) program utilizes private and public resources through strong multi-sector partnerships across the biomedical landscape. Finding the balance between social equity and business goals is key for global health partners to provide access to treatments and other resources.

Medication donation programs continue to be a major factor in achieving NTD management goals, but their financial sustainability has been brought into question as we approach the 2020 goals. Additionally, treatment development costs remain steep, while low predicted revenues add another layer of insecurity. Multi-sector partnerships are common in the NTD space as a way for pharmaceutical/biotech companies, NGOs, non-profit organizations, and government institutions to pool resources to effectively control NTDs and mitigate risks for all sectors involved. A keen understanding and strengthening of this partnership model will function as a suitable system to manage NTDs going forward.

ExL's NTDs Forum will function as a platform for participants to unpack the benefits and logistical hurdles of multi-sector partnerships in the NTD space. Attendees will explore the impact of multi-sector partnerships on sustained funding, clinical development, regulatory, and market access challenges associated with neglected tropical disease treatments.

WHO SHOULD ATTEND

This conference is designed for representatives from pharmaceutical and biotechnology companies, non-profit institutions, or a social enterprises with responsibilities in the following areas:

- Tropical Disease Program Management
- Global Health
- Global Public Health
- Global Medical Affairs
- Global Market Access
- Market Access
- Business Development
- Regulatory Affairs/Strategy
- Licensing
- Corporate Responsibility
- Strategic Planning/Partnerships
- Non-Profit Partnerships
- Liaison Collaboration
- Clinical Development/Operations/Affairs
- Program Management
- Risk Management
- Medical Information/Affairs
- Infectious Disease

This conference is also of interest to:

- Strategic/Management Consultants
- Law Firms
- Regulatory Strategy Advisors
- Clinical Research Organizations

VENUE

Hyatt Regency Boston Harbor
101 Harborside Drive
Boston, MA 02128

To make reservations, please call 888-421-1442 and request the negotiated rate for ExL's October Meetings. The group rate is available until October 4, 2017. Please book your room early, as rooms available at this rate are limited weblink: http://bit.ly/2sf11dm.

*ExL Events is not affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, housing bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL's reserved guest room block using the details provided.
Thursday, October 26, 2017

Day One

8:00 Open Registration

9:00 Conference Co-Chairs’ Opening Remarks

Veronica Arroyave, Director of Corporate Responsibility, ABBVIE FOUNDATION
Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL

9:15 Global Health Partnerships: Challenges, Benefits, and Considerations
- Implement alliance development strategies for private sector, multilateral and NGO clients
- Design tiered pricing business development strategies to improve the health of vulnerable populations
- Develop innovative market access strategies for neglected markets
- Consider policy frameworks for private sector engagement

Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL

10:00 Bridge Funding Gaps by Refining the Model of Multi–Sector Partnerships
- Evaluate the benefits and risks of multiple funding sources or temporary funding sources
- Amplify the impact pharmaceutical donations with NGO alliances to manage delivery logistics
- Find the right partnerships that meet patient needs and implementation goals
- Establish business development partnerships between several sectors
- Assess the value and practicality of government support

Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL

10:45 Networking Break

11:15 Business Development Considerations for Partnering With Patient Advocacy Groups
- Design a program with multi–sector partners to tackle regulatory and clinical trial challenges
- Construct a feasible clinical trial plan that incorporates patient advocacy organizations
- Leverage partnership resources to navigate ill-defined regulatory paths for conducting clinical trials in developing countries
- Utilize cross-functional programs to develop partnerships between industry and patient advocacy organizations
- Align priorities to allocate funds and other resources

Brian Fisher, Vice President of Operations and Corporate Partnerships, STURGE-WEBER FOUNDATION

12:15 Sustainable Revenue in Tropical Disease Medicine
- Understand the balance between humanitarian goals and sustainable revenue streams
- Discuss the development of realistic revenue streams and commercialization
- Strategize the role of licenses in the drug development plans between partners
- Increase financial benefits through partnerships that minimize manufacturing and distribution costs

Leslie Wise, Vice President of Global Healthcare Economics, ANGIODYNAMICS

1:00 Networking Luncheon

2:15 Synergistic Partnership Experiences
- Maximize resources leveraged across multi–sector partnerships
- Align yourself with the right partner most efficiently to strategically fit both your needs
- Utilize external collaboration to define strategy for platform implementation

Moderators:
Elizabeth (EJ) Ashbourne, Executive Director, PARTNERSHIP FOR QUALITY MEDICAL DONATION (PQMD)
Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL

3:00 Strategic Partnerships and Epidemiological Solutions to Maximize Treatment Efficiency
- Leverage economic health outcomes to create future funding solutions
- Strategize with local health ministries and researchers to develop access plans
- Collaborate with the public sector to gain developing countries’ government support to integrate treatment improvements into existing modes of treatment
- Understand the epidemiological and economic impact of resources leveraged across multi–sector partnerships

Uriel Kitron, Ph.D., Goodrich C. White Professor of Environmental Sciences and Department Chair of Environmental Sciences, EMORY COLLEGE OF ARTS AND SCIENCES

3:45 Networking Break

4:15 The Current Role and Future of Donation Programs in NTDs Control
- Explore the evolution of donation programs as social equity is balanced with business needs
- Maximize the impact of pharmaceutical philanthropy with partners to manage delivery and medication administration logistics
- Discuss and reduce the dependency on donation programs
- Consider financial impact of donation programs on other disease spaces
- Utilize partners’ resources to create an objective, evidence–based, and neutral distribution plan

Elizabeth (EJ) Ashbourne, Executive Director, PARTNERSHIP FOR QUALITY MEDICAL DONATION (PQMD)

4:30 Evolution and Future of Donation Programs

Donation programs are a key part of the NTD landscape and a major contributing factor to the elimination of NTDs. The 2012 London Declaration on NTDs, a global policy milestone, underscores the growing global momentum to accelerate progress toward the WHO 2020 goals. Medication donation programs continue to be a major factor in achieving those goals.

This portion of the conference program is a conversation forum dedicated to donation program expansion, development and their future. An interactive roundtable discussion will involve both the speaking faculty and audience in an effort to weave together ideas and concepts between experts. This interactive portion is the ideal format to stimulate conversation and share essential knowledge between donors, receivers, and facilitators.

- Maximize donation benefits between sectors
- Identify modes of access expansion
- Assess the long-term impact donation programs on novel treatments
- Improve and grow program implementation
- Participate in a dialog about public and private guidelines for developing exit strategies for medication donation programs
- Discuss and design the future of medication donation programs

Moderators:
Elizabeth (EJ) Ashbourne, Executive Director, PARTNERSHIP FOR QUALITY MEDICAL DONATION (PQMD)
Jodi Allison, Vice President, Global Giving, MAP INTERNATIONAL

5:45 Day One Concludes
**Day Two**

**8:45** Conference Co-Chairs' Opening Remarks

**9:00** Practical Challenges of Validating Diagnostics for Neglected Tropical Diseases
- Design a platform that can be adapted to multiple diseases as a source of sustained revenue
- Construct a feasible clinical trial plan that incorporates regional global health initiatives
- Establish an international patient foundation for clinical testing
- Navigate ill-defined regulatory paths for conducting clinical trials in developing countries

*Marco Biamonte, President, DRUGS & DIAGNOSTICS FOR TROPICAL DISEASES*

**9:45** Collaborative Role of PDPs in Strategic Partnerships to Overcome Regulatory Challenges
- Understand the business development impact of creating strategic partnerships with PDPs
- Overcome stringent regulatory hurdles associated with anti–malaria treatments
- Utilize relationships with government officials to understand regulation guidances on a granular level
- Facilitate biomedical collaborations to improve late-stage drug development strategies
- Develop partnerships with developing country institutions to implement post-registration protocols

*Wiweka Kaszubska, Ph.D., Vice President, Head of Product Development, MEDICINES FOR MALARIA VENTURE (MMV)*

**10:45** Networking Break

**11:15** Build Multi–Sector Partnerships to Increase Patient Access and Treatment Distribution for Developing Countries
- Utilize the resources leveraged for multi–sector partnership for clinical trial patient access
- Strategize with partners to access culturally and/or geographically remote clinical trial patients
- Identify what works and what doesn't work in partnership building between sectors
- Align with partners that can maintain patient care after clinical studies

*Elena Vuolo, Specialist, THE UNITED NATIONS*

**12:00** Strategic Partnerships for Conducting Clinical Trials in Developing Countries
- Determine the regulation guidelines through partnerships with local officials and doctors in developing countries
- Implement capacity-building strategies to develop clinical program design
- Share methodologies, web-based training systems, and resources of a wide cross section of internal/external partners
- Identify partners that are familiar with regulatory paths and safety guidelines in the developing world to ensure validation of clinical reports

*Fabiana Rocha, Drug Development, Clinical Manager, DRUGS FOR NEGLECTED DISEASES INITIATIVE–DNDI*

**12:45** Networking Luncheon

**1:45** The Role of Multi–Sector Partnerships in the Future of NTD Product Development
- Collaborate with entomologists to increase disease and vector vigilance
- Strategize with partners to determine how to bring the right drugs forward
- Consider what types of products do we need to design and deploy in the future

*Arnab Chatterjee, Director of Medicinal Chemistry, CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR)*

**2:30** Strategic Partnerships With Think Tanks Can Affect Policy Changes and Media Presence
- Develop think tank engagement functions to align resources and increase impact on mutual goals
- Examine the media products that can develop from engagement with influential think tanks
- Assess the influence that strategic partnerships can have on patient advocacy policies

*Shelly O'Donovan, Pharmaceutical Consultant and Former Federal and State Legislative Policy/Think Tank Engagement Lead, Public Policy Department, GSK*

**3:15** Networking Break

**4:00** NGO Multi–Sector Partnerships that Facilitate Integral Development of Public Health
- Articulate local knowledge and experiences to public institutions to improve the medication access of social vulnerability population in Colombia
- Focus on the political decision-making in health with interdisciplinary research
- Cooperate with the communities in the design and implementation of their self-management programs
- Develop intervention plans that utilize an intercultural approach and utilize public sector resources

*Pablo Montoya, Director General, SINERGIAS*

**4:45** Conference Concludes
Registration Fees for Attending ExL's Neglected Tropical Diseases Forum:

<table>
<thead>
<tr>
<th>Early Bird Rate</th>
<th>$1,895</th>
</tr>
</thead>
<tbody>
<tr>
<td>Register by Friday, September 11, 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Standard Rate</th>
<th>$2,095</th>
</tr>
</thead>
<tbody>
<tr>
<td>Register After Friday, September 11, 2017</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onsite Pricing</th>
<th>$2,295</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Includes Sales Tax and Service Fees

TERMS AND CONDITIONS: By registering for an ExL Events (“ExL”) event, you agree to the following set of terms and conditions listed below:

**REGISTRATION FEE:** The fee includes the conference, all program materials, and designated continental breakfasts, lunches and refreshments.

**PAYMENT:** Please make checks payable to: "PMA"

You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**Please Note:** There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

**CANCELLATION AND REFUND POLICY:** If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:

- **Four weeks or more:** A full refund (minus a $295 processing fee) or a voucher to another ExL event valid for 12 months from the voucher issue date.
- **Less than four weeks:** A voucher to another ExL event valid for 12 months from the voucher issue date.
- **Five days or less:** A voucher (minus a $395 processing and documentation fee) to another ExL event valid for 12 months from the voucher issue date.

To receive a refund or voucher, contact our offices at (201) 871-0474.

**CREDIT VOUCHERS:** Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applicable now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees’ behalf, the credit voucher will no longer be valid.

ExL Events does not and is not obligated to provide a credit voucher to registered attendee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

**SUBSTITUTION CHARGES:** There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare, hotel or any other expenses incurred by registrants.

ExL Events’ liability is limited to the conference registration fee in the event of a cancellation and does not include changes in program date, content, speakers and/or venue.

*The opinions of ExL’s conference speakers do not necessarily reflect those of the companies they represent, nor ExL Events.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL’s designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redistribution to other outlets without the express written permission of ExL’s designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. ExL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.